Notably, the high immune scores group had a longer OS time than the low immune scores group, suggesting that the high TYROBP expression group might present more antitumor immune cells and hence improve the clinical outcomes of osteosarcoma patients. This evidence concerns the gene TYROBP and osteosarcoma.